Docket #: S06-058
Engineered EGF polypeptides for improved epidermal and epithelial wound healing
Applications
- Treatment of chronic wounds
- Cosmetic Application
Advantages
- EGF mutants have about 30 times more receptor-binding affinity than natural EGF
Publications
- US patent 8,247,531: Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
- Cochran JR, Kim YS, Lippow SM, Rao B, Wittrup KD. Improved mutants from directed evolution are biased to orthologous substitutions. Protein Engineering, Design & Selection. 2006 Jun;19(6):245-53.
Related Technologies
- S11-262: Epidermal growth factor (EGF) mutants for wound healing and tissue engineering (details)
Related Links
Patents
- Published Application: WO2007109673
- Issued: 8,247,531 (USA)
Similar Technologies
-
Use of complement inhibition to improve wound healing S22-191Use of complement inhibition to improve wound healing
-
Deferoxamine prophylaxis for radiation-induced fibrosis S19-455Deferoxamine prophylaxis for radiation-induced fibrosis
-
Controlled Release of Bacteriophage to Treat Implant Infections S20-117Controlled Release of Bacteriophage to Treat Implant Infections